ClinicalTrials.govpublic full text
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)
pancreatic ductal adenocarcinoma (pdac), borderline resectable pancreatic cancer, pancreatic neoplasms, neoadjuvant therapy, gemcitabine, intra-arterial chemotherapy, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 886025
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.